Deerfield Management Company, L.P. (Series C) Astria Therapeutics, Inc. Call Options Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ATXS
# of Institutions
107Shares Held
48.6MCall Options Held
48KPut Options Held
9.3K-
Perceptive Advisors LLC New York, NY6.49MShares$60.8 Million1.87% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.11MShares$47.8 Million0.78% of portfolio
-
Vestal Point Capital, LP New York, NY4MShares$37.5 Million3.34% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$33.3 Million6.36% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$33 Million0.0% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $142M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...